Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025 MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine. The 4,800-square-foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting to provide an immersive experience on the history, evolution, and future of photomedicine, inc...
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP Patient Special Access Program continues during Health Canada review MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). If approved, SCENESSE® would be the first treatment for Canadian EPP patients. Health Canada review process Health Canada’s Health Products and Food Branch (HP...
Afamelanotide in fair-skinned Parkinson’s patients Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s Disease MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients, and positively affect neurons of the mid...
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years, bu...
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and Mr. Polansky, and Sean Parker and Alexandra Parker, shone a light on the groundbreaking work of CLINUVEL, a global biopharmaceutical firm whose cutting-edge melanocortin therapies transform the lives of patients at the highest risk of photoda...
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is designed to protect skin from a wide spectrum of damaging solar radiation under extreme conditions. In the first launch phase, CYACÊLLE will be available to individuals at high risk of photodamage and photoageing from ultraviolet (UV) and high energy...
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE® (afamelanotide 16mg).94% increase in NPAT; 67% increase in EBIT.Net assets increased by 11%; 16% growth in cash to $140.7 million since the start of the reporting period. Increases year on year compared to six months to 31/12/21, unless stated otherwise. All figures reported in Australian dollars, $. 31 December 202231 December...
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV) radiation, a leading factor in skin cancer and photoaging. The CUV151 study, conducted by Australian company CLINUVEL, treated nine fair-skinned volunteers with the photoprotective drug afamelan...
CLINUVEL Trial Results Show Drug Reduces DNA Damage Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extre...
Two Directors at Clinuvel Pharmaceuticals Limited bought/maiden bought 2,000 shares at 907p. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
CLINUVEL progresses vitiligo treatment program Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide – approved by US and European regulators for a rare light intolerance disorder – is being evaluated by Australian company CLINUVEL as a treatment for vitiligo patients with darker skin types. Vitiligo causes the progressive loss of skin pig...
Positive final results in stroke World-first stroke study CUV801 evaluating afamelanotide ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five patientsbrain scans (MRI-FLAIR2) in all patients show reduction of affected tissuestrong functional recovery in all five surviving patients MELBOURNE, Australia, May 03, 2022 (GLOBE NEWSWIRE) -- CLINUVEL today released positive final results of the open label pilot study (CUV801) in arterial ischemic stroke (AI...
Letter to shareholders from CLINUVEL’s CEO LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on the disproportionate decline in CLINUVEL’s value. Naturally, I experience chagrin as a substantial shareholder, but in earnest I am more concerned and engaged with the many of you who had invested 12 to 17 years ago, speculating that the Company would sustain a $2B plus valuation throughout 2022 given its financial strength to date. For the benefit of...
CLINUVEL Expands Pharmaceutical Portfolio Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply of ACTH with one of its strategic partners to meet existing global demand, and will be evaluating the potential of NEURACTHEL® for patients with neurological, endocrinological, and degenerative disorders...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
CLINUVEL expands DNA Repair Program SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its clinical program to evaluate the DNA reparative potential of afamelanotide in skin cells which have been damaged by ultraviolet (UV) and sun exposure. The program now includes patients with the rare disorders XP-V and XP-C. Having reached agreement with clinical and academic experts, CLINUVEL will generate clinical data on the safety and efficacy of SCENESSE® (afamelanotide 16mg). “X...
Summary Marketline's Neuren Pharmaceuticals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Neuren Pharmaceuticals Limited since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive ...
CLINUVEL to Trial Innovative Drug in Stroke MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of afamelanotide, developed by Australian company CLINUVEL, in arterial ischaemic stroke (AIS). The aim is to offer a treatment for patients suffering a stroke who are unable to receive treatment to dissolve or remove the underlying blood clot. AIS accounts for approximately 85% of the 15 million strokes suffered worldwide each year. “Stroke is most commonly...
CLINUVEL progresses innovative DNA Repair Program Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP). The aim of the development program is to confirm the drug’s ability to regenerate DNA of skin exposed to ultraviolet (UV) damage.1 Skin incurs DNA damage following UV exposure. Non-ionising light penetrates the nucleus of skin ce...
CLINUVEL Opens VALLAURIX R&D Centre In Singapore Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd. The extensive bespoke analytical and biological laboratories and offices will house and advance CLINUVEL’s innovative R&D projects, expanding capacities in molecular profiling, peptide chemistry, and p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.